Relationships among ET-1, PPARγ, oxidative stress and endothelial dysfunction in diabetic animals

Journal of Smooth Muscle Research

Volumn 44, Issue 2, 2008, Pages 41-55

  Matsumoto, Takayuki ^a   Kobayashi, Tsuneo ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Diabetes; Endothelin; Oxidative stress; Thiazolidinedione

Indexed keywords

ENDOTHELIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; DISEASE MODEL; DRUG POTENTIATION; EXPERIMENTAL DIABETES MELLITUS; JAPAN; MOUSE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; JAPAN; MICE; OXIDATIVE STRESS; PPAR GAMMA; RATS;

EID: 45749142878     PISSN: 09168737     EISSN: None     Source Type: Journal    
DOI: 10.1540/jsmr.44.41     Document Type: Review

References (117)

1. Bagi, Z., Koller, A. and Kaley, G. (2004). PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 286: H742-H748.
2. Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A. and Evans, R.M. (1999). PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4: 585-595.
3. Barton, M., Haudenschild, C.C., d'Uscio, L.V., Shaw, S., Munter, K. and Luscher, T.F. (1998). Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA. 95: 14367-14372.
4. Berger, J.P., Akiyama, T.E. and Meinke, P.T. (2005). PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26: 244-251.
5. Berger, J. and Moller, D.E. (2002). The mechanisms of action of PPARs. Annu. Rev. Med. 53: 409-435.
6. Bishop-Bailey, D. (2000). Peroxisome proliferators-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129: 823-834.
7. Blaschke, F., Spanheimer, R., Khan, M. and Law, R.E. (2006). Vascular effects of TZDs: new implications. Vascul. Pharmacol. 45: 3-18.
8. Blaschke, F., Takata, Y., Caglayan, E., Law, R.E. and Hsueh, W.A. (2006). Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26: 28-40.
9. Brunner, F., Bras-Silva, C., Cerdeira, A.S. and Leite-Moreira, A.F. (2006). Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol. Ther. 111: 508-531.
10. Caballero, A.E., Saouaf, R., Lim, S.C., Hamdy, O., Abou-Elenin, K., O'Connor, C., Logerfo, F.W., Horton, E.S. and Veves, A. (2003). The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52: 173-180.
11. Cai, H. and Harrison, D.G. (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87: 840-844.
12. Calnek, D.S., Mazzella, L., Roser, S., Roman, J. and Hart, C.M. (2003). Peroxisome proliferators-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23: 52-57.
13. Cho, D.H., Choi, Y.J., Jo, S.A. and Jo, I. (2004). Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma- independent signaling pathways. J. Biol. Chem. 279: 2499-2506.
14. Cohen, R.A. (2005). Role of nitric oxide in diabetic complications. Am. J. Ther. 12: 499-502.
15. De Ciuceis, C., Amiri, F., Iglarz, M., Cohn, J.S., Touyz, R.M. and Schiffrin, E.L. (2007). Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. Br. J. Pharmacol. 151: 45-53.
16. Delerive, P., Martin-Nizard, F., Chinetti, G., Trottein, F., Fruchart, J.C., Najib, J., Duriez, P. and Staels, B. (1999). Peroxisome proliferators-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85: 394-402.
17. De Vriese, A.S., Verbeuren, T.J., Van de Voorde, J., Lameire, N.H. and Vanhoutte, P.M. (2000). Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130: 963-974.
18. Diep, Q.N. and Schiffrin, E.L. (2001). Increased expression of peroxisome proliferators-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats. Hypertension 38: 249-254.
19. Diep, Q.N., El Mabrouk, M., Cohn, J.S., Endemann, D., Amiri, F., Virdis, A., Neves, M. and Schiffrin, E.L. (2001). Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats. Circulation 105: 2296-2302.
20. Drummond, G.R., Cai, H., Davis, M.E., Ramasamy, S. and Harrison, D.G. (2000). Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ. Res. 86: 347-354.
21. Du, X.L., Edelstein, D., Dimmeler, S., Ju, Q., Sui, C. and Brownlee, M. (2001). Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modulation at the Akt site. J. Clin. Invest. 108: 1341-1348.
22. Duan, S.Z., Usher, M.G. and Mortensen, R.M. (2008). Peroxisome proliferator-activated receptorgamma-mediated effects in the vasculature. Circ. Res. 102: 283-294.
23. Elmarakby, A.A., Loomis, E.D., Pollock, J.S. and Pollock, D.M. (2005). NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 45: 283-287.
24. Fontana, J., Fulton, D., Chen, Y., Fairchild, T.A., McCabe, J., Fujita, N., Tsuruo, T. and Sessa, W.C. (2002). Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of eNOS and NO release. Circ. Res. 90: 866-873.
25. Fukunaga, Y., Itoh, H., Doi, K., Tanaka, Y., Yamashita, J., Chun, T.H., Inoue, M., Masatsugu, K., Sawada, N., Saito, T., Hosoda, K., Kook, H., Ueda, M. and Nakao, K. (2001). Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158: 113-119.
26. Garcia-Cardena, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papapetropoulos, A. and Sessa, W.C. (1998). Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392: 821-824.
27. Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J.J., Johnson, L., Dietz, K.R., Nicol, C.J., Vinson, C., Gonzalez, F.J. and Reitman, M.L. (2003). Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278: 34268-34276.
28. Girnum, G.D., Domann, F.E., Moore, S.A. and Robbins, M.E. (2002). Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol. 16: 2793-2801.
29. Goto, K., Hama, H. and Kasuya, Y. (1996). Molecular pharmacology and pathophysiological significance of endothelin. Jpn. J. Pharmacol. 72: 261-290.
30. Gratton, J.P., Fontana, J., O'Connor, D.S., Garcqia-Cardena, G., McCabe, T.J. and Sessa, W.C. (2000). Reconstitution of an endothelial nitric oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. J. Biol. Chem. 275: 22268-22272.
31. He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J.M. and Evans, R.M. (2003). Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA. 100: 15712-15717.
32. Hevener, A.L., He, W., Barak, Y., Le, J., Bandyopadhyay, G., Olson, P., Wilkes, J., Evans, R.M. and Olefsky, J. (2003). Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9: 1491-1497.
33. Horio, T., Suzuki, M., Takamisawa, I., Suzuki, K., Hiuge, A., Yoshimasa, Y. and Kawano, Y. (2005). Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am. J. Hypertens. 18: 1626-1630.
34. Howarth, A.G., Wiehler, W.B., Pannirselvam, M., Jiang, Y., Berger, J.P., Severson, D., Anderson, T.J. and Triggle, C.R. (2006). A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice. J. Pharmacol. Exp. Ther. 316: 364-370.
35. Hwang, J., Kleinhenz, D.J., Lassegue, B., Griendling, K.K., Dikalov, S. and Hart, C.M. (2005). Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 288: C899-C905.
36. Hwang, J., Kleinhenz, D.J., Rupnow, H.L., Campbell, A.G., Thule, P.M., Sutliff, R.L. and Hart, C.M. (2007). The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul. Pharmacol. 46: 456-462.
37. Iglarz, M., Touyz, R.M., Amiri, F., Lavoie, M.F., Diep, Q.N. and Schiffrin, E.L. (2003a). Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelium-dependent hypertension. Arterioscler. Thromb. Vasc. Biol. 23: 45-51.
38. Iglarz, M., Touyz, R.M., Viel, E.C., Paradis, P., Amiri, F., Diep, Q.N. and Schiffrin, E.L. (2003b). Peroxisome proliferators-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid- dependent hypertension. Hypertension 42: 737-743.
39. Imai, T., Takakuwa, R., Marchand, S., Dentz, E., Bornert, J.M., Messaddeq, N., Wendling, O., Mark, M., Desvergne, B., Wahli, W., Chambon, P. and Metzer, D. (2004). Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. USA. 101: 4543-4547.
40. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50: 3-11.
41. Jay, D., Hitomi, H. and Griendling, K.K. (2006). Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 40: 183-192.
42. Kamata, K., Kanie, N., Matsumoto, T. and Kobayashi, T. (2004). Endothelin-1-induced impairment of endothelium-dependent relaxation in aortas isolated from controls and diabetic rats. J. Cardiovasc. Pharmacol. 44: S186-S190.
43. Kamata, K. and Kobayashi, T. (1996). Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes. Br. J. Pharmacol. 119: 583-589.
44. Kamata, K., Miyata, N. and Kasuya, Y. (1989). Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 97: 614-618.
45. Kanie, N. and Kamata, K. (2002). Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat. Br. J. Pharmacol. 135: 1935-1942.
46. Kanie, N., Matsumoto, T., Kobayashi, T. and Kamata, K. (2003). Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 140: 23-32.
47. Kim, Y.H., Park, K.H. and Rho, H.M. (1996). Transcriptional activation of the Cu,Zn-superoxide dismutase gene through the AP2 site by ginsenoside Rb2 extracted from a medicinal plant, Panax ginseng. J. Biol. Chem. 271: 24539-24543.
48. Kobayashi, T., Matsumoto, T. and Kamata, K. (2000). Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 131: 231-238.
49. Kobayashi, T., Matsumoto, T. and Kamata, K. (2005). The PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic models. J. Smooth Muscle Res. 41: 283-302.
50. Kobayashi, T., Taguchi, K., Yasuhiro, T., Matsumoto, T. and Kamata, K. (2004). Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44: 956-962.
51. Kou, R., Greif, D. and Michel, T. (2002). Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J. Biol. Chem. 277: 29669-29673.
52. Kubota, N., Terauchi, Y., Miki, H., Tametoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekikawa, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S. and Kadowaki, T. (1999). PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4: 597-609.
53. Lamplante, M.A., Wu, R., Moreau, P. and de Champlan, J. (2005). Endothelin mediates superoxide production in angiotensin II-induced hypertension in rats. Free Radic. Biol. Med. 38: 589-596.
54. Landmesser, U., Hornig, B. and Drexler, H. (2004). Endothelial function: a critical determination in atherosclerosis? Circulation 109: II27-II33.
55. Law, R.E., Goetze, S., Xi, X.P., Jackson, S., Kawano, Y., Demer, L., Fishbein, M.C., Meehan, W.P. and Hsueh, W.A. (2000). Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318.
56. Lee, M.E., Dhadly, M.S., Temizer, D.H., Clifford, J.A., Yoshizumi, M. and Quertermous, T. (1991). Regulation of endothelin-1 gene expression by Fos and Jun. J. Biol. Chem. 266: 19034-19039.
57. Lepailler-Enouf, D., Valdenaire, O., Philippe, M., Jandrot-Perrus, M. and Michel, J.B. (2000). Thrombin induces endothelin expression in arterial smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 278: H1606-H1612.
58. Li, L., Fing, G.D., Watts, S.W., Northcott, C.A., Galligan, J.J., Pagano, P.J. and Chen, A.F. (2003). Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107: 1053-1058.
59. Li, A.C. and Palinski, W. (2006). Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu. Rev. Pharmacol. Toxicol. 46: 1-39.
60. Maegawa, H., Nishio, Y., Nakao, K., Ugi, S., Maeda, K., Uzu, T. and Kashiwagi, A. (2007). Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr. J. 54: 613-618.
61. Makino, A. and Kamata, K. (1998). Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br. J. Pharmacol. 123: 1065-1072.
62. Makino, A. and Kamata, K. (2000). Time-course changes in plasma endothelin-1 and its effects on the mesenteric arterial bed in streptozotocin-induced diabetic rats. Diabetes Obes. Metab. 2: 47-55.
63. Makino, A., Oda, S. and Kamata, K. (2001). Mechanisms underlying increased release of endothelin-1 from aorta in diabetic rats. Peptides 22: 639-645.
64. Martens, F.M., Rabelink, T.J., op't Roodt, J., de Koning, E.J. and Visseren, F.L. (2006). TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur. Heart J. 27: 1605-1609.
65. Martens, F.M., Visseren, F.L., Lemay, J., de Koning, E.J. and Rebelink, T.J. (2002). Metabolic and additional vascular effects of thiazolidinediones. Drugs 62: 1463-1480.
66. Martin-Nizard, F., Furman, C., Delerive, P., Kandoussi, A., Fruchart, J.C., Staels, B. and Duriez, P. (2002). Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J. Cardiovasc. Pharmacol. 40: 822-831.
67. Marx, N., Duez, H., Fruchart, J.C. and Steals, B. (2004). Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94: 1168-1178.
68. Matsuda, N. and Hattori, Y. (2007). Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J. Smooth Muscle Res. 43: 117-137.
69. Matsumoto, T., Kakami, M., Noguchi, E., Kobayashi, T. and Kamata, K. (2007a). Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 293: H1480-H1490.
70. Matsumoto, T., Kobayashi, T. and Kamata, K. (2003). Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 285: H283-H291.
71. Matsumoto, T., Kobayashi, T. and Kamata, K. (2006a). A therapeutic target for microvascular complications in diabetes: endothelium-derived hyperpolarizing factor. Curr. Cardiol. Rev. 2: 185-191.
72. Matsumoto, T., Kobayashi, T. and Kamata, K. (2007b). Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr. Med. Chem. 14: 3209-3220.
73. Matsumoto, T., Kobayashi, T., Wachi, H., Seyama, Y. and Kamata, K. (2007c). Vascular NAD(P)H oxidase mediates endothelial dysfunction in basilar arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Atherosclerosis 192: 15-24.
74. Matsumoto, T., Kobayashi, T., Wakabayashi, K. and Kamata, K. (2005). Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 289: H1933-H1940.
75. Matsumoto, T., Miyamori, K., Kobayashi, T. and Kamata, K. (2006b). Apocynin normalizes hyperreactivity to phenylephrine in mesenteric arteries from cholesterol-fed mice by improving endothelium-derived hyperpolarizing factor response. Free Radic. Biol. Med. 41: 1289-1303.
76. Matsumoto, T., Noguchi, E., Kobayashi, T. and Kamata, K. (2007d). Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic. Biol. Med. 42: 993-1007.
77. Matsumoto, T., Oda, S.I., Kobayashi, T. and Kamata, K. (2004a). Flow-induced endothelium-dependent vasoreactivity in rat mesenteric arterial bed. J. Smooth Muscle Res. 40: 1-14.
78. Matsumoto, T., Wakabayashi, K., Kobayashi, T. and Kamata, K. (2004b). Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am. J. Physiol. Heart Circ. Physiol. 287: H1064-H1071.
79. Matsumoto, T., Yoshiyama, S., Kobayashi, T. and Kamata, K. (2004c). Mechanisms underlying enhanced contractile response to endothelin-1 in diabetic rat basilar artery. Peptides 25: 1985-1994.
80. Matsumoto, T., Yoshiyama, S., Wakabayashi, K., Kobayashi, T. and Kamata, K. (2004d). Effect of chronic insulin on endothelial dysfunction of basilar arteries from established streptozotocin-diabetic rats. Eur. J. Pharmacol. 504: 119-127.
81. Matsusue, K., Haluzik, M., Lambert, G., Yim, S.H., Gavrilova, O., Ward, J.M., Brewer, B. Jr., Reitman, M.L. and Gonzalez, F.J. (2003). Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111: 737-747.
82. Michalik, L., Auwerx, J., Berger, J.P., Chatterjee, V.K., Glass, C.K., Gonzalez, F.J., Grimaldi, P.A., Kadowaki, T., Lazar, M.A., O'Rahilly, S., Palmer, C.N., Plutzky, J., Reddy, J.K., Spiegelman, B.M., Steals, B. and Wahli, W. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58: 726-741.
83. Miyauchi, T. and Masaki, T. (1999). Pathophysiology of endothelin in the cardiovascular system. Annu. Rev. Physiol. 61: 391-415.
84. Murata, T., Sato, K., Hori, M., Ozaki, H. and Karaki, H. (2002). Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J. Biol. Chem. 277: 44085-44092.
85. Nakamura, T., Yamamoto, E., Kataoka, K., Yamashita, T., Tokutomi, Y., Dong, Y.F., Matsuba, S., Ogawa, H. and Kim-Mitsuyama, S. (2008). Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 51: 296-301.
86. Namikoshi, T., Satoh, M., Tomita, N., Haruna, Y., Kobayashi, S., Komai, N. Sasaki, T. and Kashihara, N. (2007). Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy. Biochem. Biophys. Res. Commun. 361: 835-840.
87. Nicol, C.J., Adachi, M., Akiyama, T.E. and Gonzalez, F.J. (2005). PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens. 18: 549-556.
88. Norris, A.W., Chen, L., Fisher, S.J., Szanto, I., Ristow, M., Jozsi, A.C., Hirshman, M.F., Rosen, E.D., Goodyear, L.J., Gonzalwz, F.J., Spiegelman, B.M. and Kahn, C.R. (2003). Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112: 608-618.
89. Okita, M., Takano, M., Shiota, Y., Nojiri, R., Sugii, M. and Matsumura, Y. (2002). A nuclear-?B inhibitor BAY 11-7082 suppresses endothelin-1 production in cultured vascular endothelial cells. Jpn. J. Pharmacol. 89: 81-84.
90. Pieper, G.M. (1998). Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 31: 1047-1060.
91. Pistrosch, F., Passauer, J., Fischer, S., Fuecker, K., Hanafeld, M. and Gross, P. (2004). In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27: 484-490.
92. Polikandriotis, J.A., Mazzella, L.J., Rupnow, H.L. and Hart, C.M. (2005). Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler. Thromb. Vasc. Biol. 25: 1810-1816.
93. Poston, L. and Taylor, P.D. (1995). Glaxo/MRS Young Investigator Prize. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin. Sci. 88: 245-255.
94. Rangwala, S.M. and Lazar, M.A. (2004). Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends. Pharmacol. Sci. 25: 331-336.
95. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. and Glass, C.K. (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82.
96. Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman, B.M. and Mortensen, R.M. (1999). PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4: 611-617.
97. Ryan, M.J., Didion, S.P., Mathur, S., Faraci, F.M. and Sigmund, C.D. (2004). PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43: 661-666.
98. Satoh, H., Tsukamoto, K., Hashimoto, Y., Hashimoto, N., Togo, M., Hara, M., Maekawa, H., Isoo, N., Kimura, S. and Watanabe, T. (1999). Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem. Biophys. Res. Commun. 254: 757-763.
99. Schiffrin, E.L. (2005). Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 288: H1037-H1043.
100. Sekiguchi, F., Yanamoto, A. and Sunano, S. (2004). Superoxide dismutase reduces the impairment of endothelium-dependent relaxation in the spontaneously hypertensive rat aorta. J. Smooth Muscle Res. 40: 65-74.
101. Sessa, W.C. (2005). Regulation of endothelial derived nitric oxide in health and disease. Mem. Inst. Oswaldo. Cruz. 100: 15-18.
102. Sharma, A.M. and Staels, B. (2007). Review: Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 92: 386-395.
103. Shi, Y., Baker, J.E., Zhang, C., Tidwell, J.S., Su, J. and Pritchard, K.A. (2002). Chronic hypoxia increases eNOS generation of NO by increasing hsp90 association and serine phosphorylation. Circ. Res. 91: 300-306.
104. Sonta, T., Inoguchi, T., Tsubouchi, H., Sekiguchi, N., Kobayashi, K., Matsumoto, S., Utsumi, H. and Nawata, H. (2004). Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic. Biol. Med. 37: 115-123.
105. Sourij, H., Zweiker, R. and Wascher, T.C. (2006). Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29: 1039-1045.
106. Stakos, D.A., Schuster, D.P., Sparks, E.A., Wooley, C.F., Osei, K. and Boudoulas, H. (2003). Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. J. Cardiol. 41: 183-190.
107. Stumvoll, M. and Haring, H.U. (2002). Glitazones: clinical effects and molecular mechanisms. Ann. Med. 34: 217-224.
108. Takahashi, S. and Mendelsohn, M.E. (2003). Calmodulin-dependent and -independent activation of eNOS by hsp90. J. Biol. Chem. 276: 9339-9344.
109. Tanaka, Y., Koike, K. and Toro, L. (2004). MaxiK channel roles in blood vessel relaxations induced by endothelium-derived relaxing factors and their molecular mechanisms. J. Smooth Muscle Res. 40: 125-153.
110. Touyz, R.M. and Schiffrin, E.L. (2006). Peroxisome proliferator-activated receptors in vascular biology - molecular mechanisms and clinical implications. Vascul. Pharmacol. 45: 19-28.
111. Triggle, C.R., Hollenberg, M., Anderson, T.J., Ding, H., Jiang, Y., Ceroni, L., Wiehler, W.B., Ng, E.S., Ellis, A., Andrew, K., McGuire, J.J. and Pannirselvam, M. (2003). The endothelium in health and disease - a target for therapeutic intervention. J. Smooth Muscle Res. 39: 249-267.
112. Vanhoutte, P.M., Feletou, M. and Taddei, S. (2005). Endothelium-dependent contractions in hypertension. Br. J. Pharmacol. 144: 449-458.
113. Walcher, D. and Marx, N. (2004). Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. Diab. Vasc. Dis. Res. 1: 76-81.
114. Walker, A.B., Chattington, P.D., Buckingham, R.E. and Williams, G. (1999). The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48: 1448-1453.
115. Willson, T.M., Lambert, M.H. and Kliewer, S.A. (2001). Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70: 341-367.
116. Woods, M., Wood, E.G., Bardswell, S.C., Bishiop-Bailey, D., Barker, S., Wort, S.J., Mitchell, J.A. and Warner, T.D. (2003). Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol. Pharmacol. 64: 923-931.
117. Yoo, H.Y., Chang, M.S. and Rho, H.M. (1999). Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene 234: 87-91.